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Abstract
Background: Men diagnosed with prostate cancer (PCa) in specific regional areas in Victoria, Australia have a poorer
five-year survival rate compared to men living elsewhere in Victoria. This study aims to describe patterns-of- presentation
and -care for men diagnosed with PCa in a specific regional Victorian area, and compare the outcomes with other
Victorian regions.
Methods: Information on consecutive men diagnosed between 2008 and 2013 was extracted from the Prostate Cancer
Outcomes Registry-Victoria. Descriptive analyses summarized diagnostic and treatment patterns of the 7,204 men with
PCa in the selected region (n = 373), metropolitan Melbourne (n = 2,565) and remaining areas of Victoria (n = 4,266) to
compare risk factors, treatments and time-taken-to-treatment.
Results: Men with PCa in the selected region were more likely to be diagnosed at older age (aged 68.6 vs 66 years in the
rest of Victoria), and incidentally rather than through case-finding PSA blood tests. They were more likely to be presented
with higher NCCN risk of the disease (High: 26 %, 24 % and 20.3 %; Very high/Metastasis: 11.8 %, 5.2 % and 5.7 % in the
study region, metropolitan Melbourne and elsewhere in Victoria, respectively).
Men in the selected region were also more likely to have a longer time from diagnosis to treatment (on average 15–30
days longer when compared to the rest of Victoria).
Conclusions: Poorer outcomes of men with PCa in this specific region might be explained by multiple factors, including
clinical-, patient-, and health-system-related. This range of explanatory factors, occurring at multiple points along the
pathway of diagnosis and detection, suggests that interventions to improve outcomes for PCa in regional areas such as
this need to be systematic. Interventions specifically addressing any one factor in isolation are unlikely to have much
effect.
Keywords: Prostate cancer, Regional, Clinical registry, Patterns-of-care
Abbreviations: ADT, Androgen deprivation therapy; AS, Active surveillance; BT, Brachytherapy; DHHS, Department of
health and human services; EBRT, External beam radiation therapy; GP, General practitioner; HDR, High-dose rate
brachytherapy; ICS, Integrated cancer service; IQR, Interquartile range; LDR, Low-dose rate brachytherapy; NCCN, National
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comprehensive cancer network; OR, Odds ratio; PCa, Prostate cancer; PCOR-Vic, Prostate cancer outcomes registry –
Victoria; PSA, Prostate-specific antigen; SEIFA, Socio-economic index of advantage and disadvantage; TRUS, Transrectal
ultrasonography of the prostate; TURP, Transurethral resection of the prostate; WW, Watchful waiting
Background
Australia and New Zealand have among the highest inci-
dence of prostate cancer (PCa) in the world with a com-
bined age-standardised incidence rate of 104.4 cases per
100,000 [1]. Previous studies demonstrated statistically
significant and increasing mortality excess for PCain re-
gional and rural areas in Australia and New Zealand [2, 3].
Haynes et al. [4] investigated cancer survival in New
Zealand and showed that survival from PCa was poor in
men living distantly from primary care and cancer centres.
Geographic patterns of PCa mortality and variations in ac-
cess to medical care were also examined in the US by
Jemal et al. and Singh et al. [5, 6]. These studies showed
that men in non-metropolitan counties generally had
higher death rates and incidence of late-stage disease and
lower prevalence of prostate-specific antigen (PSA)
screening than in metropolitan areas. Rural and urban in-
equalities and increased PCa mortality were explained by
the variation in screening, management of the disease and
access to medical services and primary care [7, 8].
There is disparity between PCa survival in regional
areas compared with metropolitan areas across Australia
(5-year relative survival = 87.7 % vs 91.4 %, p < 0.001) [9].
According to the Victorian Cancer Registry (VCR) data,
[10] the relative survival for one regional geographic re-
gion in Victoria, defined by a Government cancer health
service boundary (an Integrated Cancer Service [ICS]
area) five years after the diagnosis was approximately by
7 % lower than in metropolitan Melbourne (93 %, 95 % CI
92–93 %) and amongst the lowest in regional Victoria.
Potential causes for worse outcomes in this particular
ICS could include epidemiological errors (i.e. wrong clas-
sification and coding of the disease); differences in the
makeup of the population (i.e. more men with PCa risk
factors living in this area); differences in disease at diagno-
sis (i.e. men are diagnosed with more advanced disease);
differences in access to treatment (i.e. less men have cura-
tive treatment); and differences in patterns of treatment
(i.e. some forms of treatment not available). The aim of
this study was to evaluate factors associated with poorer
survival outcomes in one regional Victorian ICS and com-
pare the outcomes with other Victorian regions.
Methods
Study region
The selected regional ICS (further referred to as “a study
region”) covers over 18 % of Victoria’s total landmass. In
2011, the region’s estimated resident population was
270,512 and represented ~5 % of Victoria’s total popula-
tion [11]. By 2026, its population is projected to increase
by 21 % compared with an overall state average increase
of 23 %. This region comprises of 16 health services.
Victorian prostate cancer registry
The Victorian Prostate Cancer Registry (now termed the
Prostate Cancer Outcomes Registry-Victoria, PCOR-Vic)
was established in 2009 as a rapid case-ascertainment
registry to monitor patterns- and quality- of-care for
Victorian men diagnosed with PCa. The registry collects
data on PCa cases from 38 metropolitan and regional pub-
lic and private hospitals in Victoria. Based on the latest
update from Victorian Cancer Registry [12], these sites ac-
count for about 70 % of incidence PCa cases in that State,
and more than 10,000 men have been accrued. Registry
recruitment is linked with mandatory notification of
cancer status to the population-based Victorian Cancer
Registry. Details of the registry, including methods for
data collection, are described elsewhere [13].
Inclusion and exclusion criteria
Men from the PCOR-Vic were included in the study if
they had been diagnosed with a pathological diagnosis of
PCa between August 2008 and July 2013 and were noti-
fied to the registry after the date on which the relevant
hospital began contributing data. An explanatory state-
ment, available in 12 common languages, was sent to
men who were eligible to participate in the study about
9 months after they had been diagnosed. The statement
invited them to participate in the PCOR-VIC and pro-
vided an opt-out option. Consent was obtained from cli-
nicians to include all their patients into the registry.
Patients were ineligible if their diagnosing or treating
doctor informed the registry that they were not capable
of providing consent.
Recruitment and data collection
An explanatory statement and accompanying letter was
sent to men who were eligible to participate in the study.
A waiver of consent was provided to enable collection of
diagnostic and treatment details on all men with PCa,
who (1) died before consent could be sought; and (2)
were diagnosed via a transurethral resection of the pros-
tate (TURP) and in whom their treating clinician has re-
quested not to contact the patient. Men were able to opt
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out of the registry at any time. Histopathological data
were captured through hospital information systems and
pathology reports. Clinical information was collected
from medical records by trained data collectors. Treat-
ments provided within 12 months of diagnosis were in-
cluded in the analysis. More detailed information about
the steps of data collection is provided elsewhere [13].
Statistical analysis
The National Comprehensive Cancer Network (NCCN)
risk criteria for disease progression were used to classify
patients into low-, intermediate- and high-risk disease
(Table 1) [14].
Where the clinical T category was not recorded, if the
Gleason score was ≤6 and the PSA concentration was
<10 ng/mL, the patient was deemed to be at low risk for
disease progression. In our study for data analysis purposes
PSA levels were grouped into five categories: (1) <1 ng/mL,
(2) 1–4 ng/mL, (3) 4.01–10 ng/mL, (4) 10.01–20 ng/mL,
and (5) >20 ng/mL. Four Gleason score categories were
used in this study: (1) score <7, (2) score = 7 (3 + 4), (3)
score = 7 (4 + 3), and (4) ≥8.
Treatments provided within 12 months of diagnosis
were included in the analysis. The following treatment
categories were used: (1) Surgery (radical prostatec-
tomy), (2) External Beam Radiotherapy Therapy and/or
high dose radiation (EBRT/EBRT +HDR), (3) EBRT +
Surgery, (4) Low dose radiation (LDR), (5) HDR, (6)
Brachytherapy, dose unknown (BT-Unknown), (7) An-
drogen Deprivation Therapy (ADT), (8) Chemotherapy,
(9) Active Surveillance (AS), Watchful Waiting (WW)
and (10) Others (i.e. high intensity focused ultrasound
etc.). For those patients whose treatment information
was not recorded, treatment type was coded as “un-
known”. Active treatment was defined as any Surgery,
EBRT, BT, HDR, LDR, ADT or other treatment, but ex-
cluded no active treatment option. Note that we could
not reliably differentiate watchful waiting from active
surveillance, and thus we have called them “no active
treatment”. Where treatment information was missing
(i.e. the treatment field in the registry was left blank) it
was coded as ‘unknown’ rather than no active treatment.
More detailed information about the treatment types is
provided elsewhere [13].
Distance to primary treatment facility was calculated
using the patient’s residential address postcode and the
hospital location on Whereis®. The Whereis® is one of
Australia’s most popular free navigation applications,
which provides maps and coordinates of Australian
cities, towns and travel destinations with driving direc-
tions and traveller information [15].
Descriptive statistics summarized these variables in
men from the study region, metropolitan Melbourne
and the rest of Victoria. Analyses of variance and X2
tests for independence were used to examine demo-
graphic, diagnostic and treatment characteristics and
their differences. Kruskal–Wallis and Mann–Whitney U
tests were used to compare time and distance to treat-
ment amongst the groups. Post-hoc tests were used to
evaluate pairwise differences between categories for each
group of patients. Type 1 errors were controlled using
the Bonferroni approach, setting the level of significance
to P = 0.0033.
A binary logistic regression analysis was performed to
assess the impact of a number of factors (both individually
and together) on the likelihood of men being offered an
active treatment (i.e. no AS/WW) in the selected region.
In the present study, the model predicted active treatment
(i.e. “active treatment” outcome was set as 1, and all other
treatments as 0) from demographic characteristics and
diagnostic characteristics. All individual factors and their
interactions that were significantly predictive, were added
to the multivariate model. Univariate analysis (step 1) for
all variables and their interactions was conducted to iden-
tify significant individual predictors, which yielded six sig-
nificant potential factors and interactions that might be
associated with men receiving active treatment of the dis-
ease. The six category variables were then added into a
multivariate model (step 2).
Stata/IC 12.1 (StataCorp, TX, USA) was used for all
analyses.
Results
A total of 10,827 men with PCa were notified to the
PCOR-Vic between August 2008 and July 2013. Of
these, 3,610 (33.3 %) cases were excluded from the data
analysis as their diagnosis was confirmed before the
commencement of the study and 13 (0.12 %) patients
opted out. The records of 7,204 eligible and consented
men diagnosed in three regional and one metropolitan
ICS were included in the analysis. 373 (5.2 %) of these
men were diagnosed in the study region, 2,565 (35.6 %)
were from metropolitan Melbourne and the remaining
Table 1 Risk adjustment model adopted among men with PCa
from clinical registries in Victoria
Variable NCCN
Low Clinical T1–T2a stage AND GS 2–6
AND PSA level <10 ng/mL
Intermediate Clinical T2b–T2c stage OR GS = 7
OR PSA level 10–20 ng/mL
High Clinical T3a stage OR GS 8–10
OR PSA level >20 ng/mL
Very high (locally advanced) Clinical T3b–T4 Any T, N1
Metastatic Any T, Any N, M1
NCCN, National Comprehensive Cancer Network; GS, Gleason Score; PSA,
Prostate Specific Antigen
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4,266 (59.2 %) patients were diagnosed elsewhere in
Victoria.
Demographic and diagnostic characteristics
The average and median age of PCa men in the study re-
gion was significantly higher when compared to other
Victorian men (Table 2). The median (IQR) age at diag-
nosis of men in the study region was 68.4 (45–92.5)
years compared to 66 (38–96) in Melbourne and 66
(39–95) in the rest of Victoria.
Men diagnosed in the region had lower rates of socio-
economic advantage using Socio-Economic Advantage
and Disadvantage (SEIFA) categories [16], with more
than half the men (54 %) in the study region from the
no more than the 4th decile of SEIFA scores whereas, for
example, in the men from metropolitan regions more
than half (54 %) were in the highest two deciles, with
fully 25 % in the highest decile of SEIFA scores. The
SEIFA score is a composite of a number of average mea-
sures within an area including equivalent household in-
come, occupancy type, level of educational attainment,
level of employment/unemployment, occupational skill
level, crowding, car ownership, marital status, housing
and income support.
In addition the vast majority (87.4 %) of men in the
study region was treated in public hospitals, which was
different from metropolitan Melbourne and the rest of
Victoria; men in the study region were more than four
times less likely to be treated in a private hospital than
men in metropolitan Victoria or other regional areas in
Victoria.
The vast majority of men in the study region were di-
agnosed via TRUS; although a significantly higher per-
centage of new diagnoses was detected via TURP when
compared to metropolitan Melbourne or other Victorian
regions (20.7 %, 16.2 % and 6.8 % respectively).
When compared to the other regions, the study region
also presented with a higher proportion of men with ele-
vated levels of PSA (>20 ng/mL) at diagnosis (19.3 %,
11.7 % and 10 % respectively). Men in the study region
were also more likely to be diagnosed with a higher
Gleason score (8–10) than those diagnosed elsewhere in
Victoria (27.6 %, 22.5 % and 18.3 % respectively) and
presented with higher NCCN risk of the disease (High:
26 %, 24 % and 20.3 %; Very high/Metastasis: 11.8 %,
5.2 % and 5.7 % in the study region, metropolitan
Melbourne and elsewhere in Victoria, respectively).
Treatment characteristics
Treatment modalities, time to the initial treatment and
travel distance are summarized in the Table 3. A significantly
lower proportion of men with a low risk disease (19.2 %) in
the study region were treated with a radical prostatectomy
when compared to metropolitan Melbourne (29.7 %) and
the rest of Victoria (43.9 %). Men in this area had to travel a
longer distance (median [IQR] of 31.6 [18.9-69.3] km) to
their health services provider, compared to those treated in
metropolitan Melbourne (11.8 [6.2-25.9] km), or the rest of
Victoria (21.6 [9.1-55.5] km).
By comparing men in the same “risk group” across re-
gions, we can to some extent adjust for difference in
management patterns overall that might be influenced
by the more advanced higher grade disease seen in the
region, by comparing more “like with like”. In the risk
group in which attempts at curative treatment are most
clearly indicated, the intermediate risk group, men had
different management patterns. There were a signifi-
cantly lower proportion of men in the study region -
nearly half as frequent - who undertook a prostatectomy
[(27.4 vs 51.0 % vs 58.5 %). EBRT treatment as also at
least a third less frequent (10.4 % vs 15.1 % vs 18.3 %)
when compared to metropolitan Melbourne or the rest
of Victoria, even within this identical intermediate risk
group. As a consequence, there was also a significantly
higher proportion of men (more than twice as likely) did
not receive active treatment in this particular region
(31.9 % vs 15.1 % vs 10.7 %). For these men, the median
[IQR] amount of time between diagnosis and treatment
in the study region was notably longer: 101 (56–191) vs
71.5 (44–119) vs 61 (39–103) days in metropolitan
Melbourne and the rest of Victoria respectively. Men
with intermediate risk PCa in the study region also
needed to travel more than four times longer distances
to their treating institution (56.4 [23.1-114.9] km) than
those in metropolitan Victoria.
In a high-risk cancer group, 13.4 % of men undertook
a prostatectomy in the study region, significantly less
(less than half as common) than in metropolitan
Melbourne (27.3 %) or in the rest of Victoria (36.1 %).
There men were more than twice as likely to be treated
with androgen deprivation (ADT), 35.1 %, compared to
14.9 % in metropolitan Melbourne and 9.1 % in the rest
of Victoria. A median [IQR] amount of time between
diagnosis and treatment was 57 [34–90] days, signifi-
cantly longer than in metropolitan Melbourne (49.5
[31–84.25] days) or in the rest of Victoria (43 [27–65]
days). Men in the selected ICS travelled a median [IQR] of
42.3 [19–82.7] km, almost four-time further than those
treated in metropolitan Melbourne (11.7 [6.2-25.7] km), or
twice as far as in the rest of Victoria (20.8 [9.8-61.3] km).
In a very high/metastatic risk group patterns-of- care
were similar as in other groups, with more patients in
the study region (52.3 %) being treated with ADT when
compared to 30.8 % in metropolitan Melbourne, or
34.3 % in the rest of Victoria. The median [IQR] amount
of time to the first treatment in the study region was 27
[6–67.5] days, 27 [9–58.5] in metropolitan Melbourne
and 19.5 [7–50] elsewhere. Men needed to travel the
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Table 2 Demographic and clinical characteristics of men with PCa in the study region, metropolitan Melbourne and the rest of Victoria
Study region, n (%) Metropolitan, n (%) Rest of Victoria, n (%) p
Included into the study 373 (5.2 %) 2,565 (35.6 %) 4,266 (59.2 %) 0.000
Age groups 0.000
< 55 24 (6.4 %) 293 (11.4 %) 549 (12.9 %)
56–65 117 (31.4 %) 896 (34.9 %) 1,551 (36.4 %)
65–75 145 (38.9 %) 909 (35.4 %) 1,632 (38.3 %)
> 76 87 (23.3 %) 467 (18.2 %) 534 (12.5 %)
Age (mean, SD) 68.6 (8.9) 66.7 (9.3) 65.5 (8.8) 0.000
SEIFA 0.000
Lowest 10 % (0–10 %) 70 (18.9 %) 93 (3.6 %) 217 (5.1 %)
Lowest 11–20 % 57 (15.4 %) 68 (2.7 %) 197 (4.6 %)
Lowest 21–30 % 9 (2.4 %) 77 (3.0 %) 232 (5.5 %)
Lowest 31–40 % 64 (17.3 %) 127 (5.0 %) 392 (9.2 %)
Lowest 41–50 % 113 (29.9 %) 160 (6.2 %) 293 (6.9 %)
Highest 51–60 % 32 (8.6 %) 119 (4.6 %) 291 (6.8 %)
Highest 61–70 % 18 (4.9 %) 208 (8.1 %) 496 (11.7 %)
Highest 71–80 % 8 (2.2 %) 325 (12.7 %) 546 (12.8 %)
Highest 81–90 % 1 (0.3 %) 747 (29.0 %) 907 (21.2 %)
Highest 10 % (91–100 %) 1 (0.3 %) 641 (25.0 %) 695 (16.2 %)
Type of hospital 0.000
Private 47 (12.6 %) 1,390 (54.2 %) 2,822 (66.2 %)
Public 326 (87.4 %) 1,175 (45.8 %) 1,444 (33.8 %)
Method of diagnosis 0.000
TRUS 285 (76.4 %) 2,081 (81.1 %) 3,919 (91.9 %)
TURP 77 (20.7 %) 416 (16.2 %) 291 (6.8 %)
Other 11 (2.9 %) 68 (2.7 %) 56 (1.3 %)
PSA (ng/mL) 0.000
< 4 45 (12.1 %) 427 (16.6 %) 688 (16.1 %)
4.01–10 176 (47.2 %) 1,337 (52.1 %) 2,408 (56.4 %)
10.01–20 74 (19.8 %) 395 (15.4 %) 679 (15.9 %)
> 20.01 72 (19.3 %) 301 (11.7 %) 426 (10.0 %)
Unknown 6 (1.6 %) 105 (4.1 %) 65 (1.5 %)
Gleason score 0.000
< 7 155 (41.6 %) 851 (33.2 %) 1,641 (38.5 %)
7 (3 + 4) 69 (18.6 %) 736 (28.7 %) 1,306 (30.6 %)
7 (4 + 3) 41 (10.9 %) 394 (15.4 %) 535 (12.6 %)
≥ 8 103 (27.6 %) 577 (22.5 %) 782 (18.3 %)
Unknown 5 (1.3 %) 7 (0.3 %) 2 (0.0 %)
NCCN risk group 0.000
Low 73 (19.6 %) 478 (18.6 %) 911 (21.4 %)
Intermediate 113 (30.3 %) 1,064 (41.5 %) 1,887 (44.2 %)
High 97 (26.0 %) 616 (24.0 %) 867 (20.3 %)
Very high/Metastatic 44 (11.8 %) 133 (5.2 %) 245 (5.7 %)
Unknown 46 (12.3 %) 274 (10.7 %) 356 (8.3 %)
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Table 3 Treatment modalities, stratified by NCCN risk group, of men with PCa in the study region, metropolitan Melbourne and the rest of Victoria





























46 (63.0 %) 244 (51.0 %) 337 (37.0 %) 36 (31.9 %) 161 (15.1 %) 201 (10.7 %) 8 (8.2 %) 45 (7.3 %) 44 (5.1 %) 1 (2.3 %) 4 (3.0 %) 3 (1.2 %)
Surgery
(Prostatectomy)
14 (19.2 %) 142 (29.7 %) 400 (43.9 %) 31 (27.4 %) 543 (51.0 %) 1,104 (58.5 %) 13 (13.4 %) 168 (27.3 %) 313 (36.1 %) 2 (4.5 %) 9 (6.8 %) 21 (8.6 %)
EBRT/EBRT
+ HDR
5 (6.8 %) 33 (6.9 %) 56 (6.1 %) 23 (10.4 %) 161 (15.1 %) 345 (18.3 %) 35 (36.1 %) 233 (37.8 %) 311 (35.9 %) 11 (25.0 %) 60 (45.1 %) 109 (44.5 %)
EBRT + Surgery 1 (1.4 %) 5 (1.0 %) 26 (2.9 %) 3 (2.7 %) 78 (7.3 %) 108 (5.7 %) 5 (5.2 %) 60 (9.7 %) 96 (11.1 %) 0 (0.0 %) 6 (4.5 %) 9 (3.7 %)
LDR 5 (6.8 %) 22 (4.6 %) 69 (7.6 %) 7 (6.2 %) 53 (5.0 %) 68 (3.6 %) 0 (0.0 %) 0 (0.0 %) 1 (0.1 %) 1 (2.3 %) 0 (0.0 %) 0 (0.0 %)
HDR 0 (0.0 %) 0 (0.0 %) 1 (0.1 %) 1 (0.9 %) 6 (0.6 %) 3 (0.2 %) 0 (0.0 %) 1 (0.2 %) 1 (0.1 %) 1 (2.3 %) 0 (0.0 %) 1 (0.4 %)
BT-Unknown 1 (1.4 %) 8 (1.7 %) 5 (0.5 %) 0 (0.0 %) 8 (0.8 %) 6 (0.3 %) 0 (0.0 %) 1 (0.2 %) 2 (0.2 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
ADT 0 (0.0 %) 3 (0.6 %) 2 (0.2 %) 9 (8.0 %) 13 (1.2 %) 23 (1.2 %) 34 (35.1 %) 92 (14.9 %) 79 (9.1 %) 23 (52.3 %) 41 (30.8 %) 84 (34.3 %)
Chemotherapy 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (1.0 %) 1 (0.2 %) 1 (0.1 %) 4 (9.1 %) 5 (3.8 %) 13 (5.3 %)
Other 0 (0.0 %) 5 (1.0 %) 4 (0.4 %) 0 (0.0 %) 6 (0.6 %) 2 (0.1 %) 0 (0.0 %) 0 (0.0 %) 1 (0.1 %) 0 (0.0 %) 1 (0.8 %) 0 (0.0 %)
Not known 1 (1.4 %) 16 (3.3 %) 11 (1.2 %) 3 (2.7 %) 35 (3.3 %) 27 (1.4 %) 1 (1.0 %) 15 (2.4 %) 18 (2.1 %) 1 (2.3 %) 7 (5.3 %) 5 (2.0 %)
Total 73 (100 %) 478 (100 %) 911 (100 %) 113 (100 %) 1,064 (100 %) 1,887 (100 %) 97 (100 %) 616 (100 %) 867 (100 %) 44 (100 %) 133 (100 %) 245 (100 %)
Median (IQR) days
to initial treatment
N/A N/A N/A 101 (56–191) 71.5 (44–119) 61 (39–103) 57 (34–90) 49.5 (31–84.25) 43 (27–65) 27 (6–67.5) 27 (9–58.5) 19.5 (7–50)
Median (IQR) km
to treating hospital













median [IQR] distance of 39.4 [19.2-80.8] km to their
treatment institution, longer than in metropolitan
Melbourne (11.4 [5.5-24.7] km) or in the rest of Victoria
(25.6 [11.2-71.6] km).
Regression analysis of factors determining treatment type
Table 4 summarizes the contributions of factors in the
univariate and multivariate model to men receiving ac-
tive treatment.
A full multivariate model containing all six category var-
iables was statistically significant, χ2(17, N = 6,528)
=1491,869 p < 0.05) indicating ability to distinguish be-
tween men with PCa who had active treatment (N =
5,751) vs those with no active treatment. The model ex-
plained between 21 % (Cox and Snell R Square) and 34 %
(Nagelkerke R Square) of the variance in treatment type.
When compared to the selected region, men diag-
nosed in metropolitan areas had nearly twice the odds of
receiving active treatment (OR = 1.89, 95 % CI, 1.35-
2.64), and those in the rest of Victoria were even at
higher odds, OR = 2.59, 95 % CI, 1.86-3.61). Men older
than 75 years of age were nearly 90 % less likely to re-
ceive active treatment, compared to younger men of
55 years or less, OR = 0.13, (95 % CI, 0.09-0.17). Men
with PCa were also more likely to receive an active treat-
ment in public hospitals, OR = 1.44, (95 % CI, 1.22-1.69).
Those men whose diagnosis was detected via TURP
were less likely to receive an active treatment, OR = 0.22,
(95 % CI, 0.17-0.28) than men diagnosed via TRUS.
When combined with other factors, higher NCCN Risk
levels were also associated with an increased likelihood
of men receiving an active treatment. For example, men
Table 4 Significant factors associated with the likelihood of active treatment in men with PCa (NS – Not Significant)
Univariate model Multivariate model
Factors Odds Ratio CI at 95 % Odds Ratio CI at 95 %
Region
Selected Region (Ref) 1 1
Metropolitan 1.53 1.21-1.94 1.89 1.35-2.64
Rest of Victoria 2.21 1.74-2.78 2.59 1.86-3.61
Age
< 55 (Ref) 1 1
56-65 0.76 0.61-0.94 0.62 0.47-0.80
65-75 0.75 0.61-0.93 0.41 0.31-0.53
> 76 0.41 0.33-0.52 0.13 0.09-0.17
Type of hospital
Private (Ref) 1 1
Public 1.52 1.34-1.72 1.44 1.22-1.69
Method of diagnosis
TRUS (Ref) 1 1
TURP 0.17 0.15-0.20 0.22 0.17-0.28
Other 1.44 0.85-2.44 0.79 0.35-1.76
NCCN Risk
Low (Ref) 1 1
Intermediate 5.03 4.34-5.84 6.12 5.16-7.25
High 11.48 9.12-14.45 27.69 20.81-36.87
V.high/Metastatic 38.85 19.15-78.82 138.39 65.32-293.22
Region × NCCN Risk
Selected Region × Low (Ref) 1 NS NS
Metropolitan × Intermediate 3.61 2.97-4.38 NS NS
Metropolitan × High 8.16 5.94-11.23 NS NS
Metropolitan × V.high/Metastatic 20.75 7.64-56.42 NS NS
Rest of Victoria × Intermediate 5.39 4.53-6.43 NS NS
Rest of Victoria × High 12.04 8.75-16.55 NS NS
Rest of Victoria × V.high/Metastatic 51.92 16.56-162.79 NS NS
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with v.high/metastatic disease had extremely high odds
of receiving active treatment than men diagnosed with
low risk disease, OR = 138.39, (95 % CI, 65.32-293.22).
Univariate model also revealed, that compared to men
in the selected region diagnosed with low risk disease,
those in the other areas, and at higher risk of the disease
were more likely to receive an active treatment.
Discussion
Higher death rates from prostate (and other) cancers
occur in patients from non-metropolitan regions. The
population-based PCOR-Vic has enabled more precise
identification of the underlying factors in one selected ICS
in regional Victoria. We found that men in the study re-
gion were startlingly lower in measures of socio-economic
advantage. They were older. A higher percentage of newly
PCa cases in the study region (almost a fifth) were de-
tected during TURP, a procedure performed to alleviate
symptoms of urinary obstruction and not done primarily
usually because PCa. Although TURP is generally not used
to detect PCa anymore, as it makes a poor tool for early
cancer detection [17], it used to be a common mean of de-
tection of PCa before PSA screening was introduced.
We also found that men in the study region presented
with a significantly higher level of PSA levels and
Gleason score at diagnoses when compared to other
Victorian regions, which supports previous research
findings that men in rural and regional areas are more
likely to have elevated PSA and Gleason score [18–21].
Overall, men in the study region presented for treatment
at a more advanced disease stage when compared to the
rest of Victoria, similarly to the findings reported by
Baade and Coory, [2, 3] showing that men living in re-
gional areas tend to be diagnosed at advanced stages of
the disease. A possible reason for higher rates of a more
advanced disease in the study region could possibly be
due to issues of high PSA testing rates in metropolitan
areas [2, 18].
Men in the study region, in the low and intermediate dis-
ease groups, were significantly less likely to undergo active
treatment. There is emerging evidence that many men with
early stage disease are appropriately managed with AS ra-
ther than having active invasive treatment [22, 23]. Yet,
since the rates of no treatment are higher than the rates of
no treatment in metropolitan Victoria, particularly in the
intermediate risk group (where AS would not usually be
recommended), it may be that higher rates of non-
treatment represent a significant proportion of men diag-
nosed in the region are not having treatment as would be
appropriate, rather than being placed on systematic pro-
gram of active follow-up and surveillance as would be done
if they were on AS. Variability in treatment patterns in dif-
ferent regions could also potentially reflect the managing
clinicians’ treatment preferences, perhaps different in the
region than other parts of Victoria, since this factor is
known to be a strong determinant of the treatment re-
ceived [24, 25].
There was a notable time delay between diagnosis and
treatment in men with intermediate/very high risk dis-
ease in the study region when compared to the rest of
Victoria. While reasons for such delay are unknown -
the findings may reflect a preference by their treating
doctor to manage the disease conservatively or that men
themselves are more reluctant to take up the option for
active treatment than in other areas of Victoria - delays
of more than 30–60 days can adversely affect patho-
logical outcomes in men in these risk groups treated
with radical prostatectomy [26].
Men in the study region also travelled much longer
distances for their treatment, which could have influ-
enced their choice of treatment and determined their
health outcomes. Previous studies showed that prognosis
and outcomes from PCa are known to be worse for men
living in rural areas and needing to travel longer dis-
tances to their treatment providers [4, 27]. Longer time
and distance required to travel could act as an economic
and financial barrier in men’s treatment choice, which
may potentially explain why, compared with metropol-
itan regions, there are more men in the study region
with high risk disease but who did not receive active
treatment. The disadvantaged socio-economic category
for many men in the region could be imagined to
worsen barriers caused by distance.
As suggested by Ng et al. [28], the reasons for such
discrepancies as we noted in treatment and outcomes
between metropolitan and regional areas could possibly
be explained by clinical-, patient-, and health-system-
related factors. Potential patient-related barriers to PCa
care could include not consulting a general practitioner
(GP) in a timely manner [29], a lack of desire for treat-
ment due to a ‘I will be OK’ attitude, or financial/time
barriers if the care is only available outside the patient’s
regional area, thus requiring considerable time and
travel expenses [15]. Urban–rural disparities in PCa inci-
dence and mortality may arise from differences in demo-
graphic and socioeconomic characteristics of these two
groups that may influence access to and utilization of
diagnostic and treatment services [30].
It is not surprising that men in regional areas in
Australia face distinct health issues because of their loca-
tion, work, and lifestyle. There is evidence that these
men are more likely to experience chronic health condi-
tions and have more risk factors for serious disease than
their metropolitan counterparts. For example, epidemio-
logical studies of Begg and Beard have demonstrated
that rural dwellers are more likely than metropolitan
dwellers to report daily smoking and risky drinking be-
havior, [31, 32] are less likely to possess an adequate
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level of health literacy and have higher mortality rates
from injury, cardiovascular disease and diabetes [33].
The other potential reason could be a limitation on
GPs referral choice, and issues concerning the quality of
care due to potential for impediments to professional
development of regional doctors and specialists [28]. It
may be that specialists, diagnostic equipment and other
medical technology, and operating rooms are much
more restricted in the regional areas. Internationally, pa-
tients with cancer are increasingly being managed by
multidisciplinary teams, allowing the use of varying pro-
fessional skills with numerous benefits for the patient
[34] and this approach is promoted by the Victorian
Department of Health and Human Services. A lack of
uro-oncology multidisciplinary meetings in the selected
study region could also be associated with poorer out-
comes in men with PCa [16].
The Australian and Victoria Governments as well as
community groups have been determined to allocate re-
sources to reduce inequity in health outcome [35]. This
highlights the importance of our work. Our study has
demonstrated that there are interlinked chain of factors
that are associated with the poorer outcomes: the men
are older, they are startlingly more likely to be in disad-
vantaged socio-economic groups, the live much further
away from specialist health care providers, they are
much more likely to be diagnosed “by accident”, as it
were, and then they wait much longer for treatment.
They have more advanced and more aggressive disease
when they do get diagnosed; but even adjusting for this,
they are much more likely not to receive any attempt at
curative treatment, and much more likely to be treated
in a public hospital. The health services in the region
have fewer services available for the care of men with
PCa. Hitherto, work has established the disparities in
outcome in regional areas, but the causes were mostly
supposition in the absence of data. Registries provide the
data on the factors associated with these outcomes.
The major strength of this study is the use of clinical
registry data, containing a detailed diagnosis and treat-
ment information of the patients with PCa. The PCOR-
Vic enables rapid and reliable ascertainment of patterns
of care and quality of life data of men diagnosed with
PCa and reports back to treating clinicians in regional
and metropolitan Victoria [13]. However, some limita-
tions to this study also need to be noted. Firstly, there
were a relatively small number of PCa men in the study
region. Another important limitation is that we did not
seek to identify reasons why men received no treatment
within 12 months of diagnosis in the study region. It
may be that they were receiving AS, had decided not to
pursue active curative treatment, were awaiting therapy
on the basis of their PSA level taken at 12 months, or
were inadequately managed. Finally, we were unable to
investigate other factors, such as obesity, smoking habits
or alcohol consumption in the study region as the regis-
try does not collect such information.
This study has identified a number of key areas of dif-
ference in the study region. Identifying these differences
allows logical plans for where the effort needs to be
made to enable improvement, and where more informa-
tion is needed. The findings of this study have been
shared with health service providers and policy-makers
in the study region. They have an on-going strategy to
address many of the key points identified, to better pro-
vide health care services for men diagnosed with PCa in
the region. A project is underway to better understand
factors associated with why men are presenting with
more advanced PCa disease than in other areas of
Victoria. This multifaceted project will involve patients
living in the region and their GPs. It is important that
we understand reasons for this so that interventions can
be targeted to areas of greatest need.
Conclusions
The PCOR-Vic has enabled for the first time clarity around
the factors associated with PCa in an Australian regional lo-
cation, documenting many structure, process or outcome
measurements where the location performs worse than
other metropolitan or regional areas in Victoria. It suggests
plans to improve outcomes need to be made on a system-
atic basis. Registries such as the PCOR-Vic provide vital
on-going insight on how resources are best allocated to im-
prove the lot of men diagnosed with PCa.
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